Novartis wins U.S. approval for breast cancer drug; to compete with Pfizer's Ibrance

ZURICH (Reuters) - Novartis has won U.S. Food and Drug Administration approval for Kisqali to treat postmenopausal women who have a difficult-to-treat form of breast cancer, challenging U.S. rival Pfizer's Ibrance.

Novartis wins U.S. approval for breast cancer drug; to compete with Pfizer's Ibrance
Read More


Bagikan Berita Ini